{
Viatris Inc.

Companies

}
001122334455554433221100
001122334455554433221100
Symbol VTRS
Name Viatris Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Pharmaceuticals
Market NASDAQ Global Select
Country United States
State PA
City Canonsburg
Zipcode 15317
Website http://www.viatris.com
Track all markets on TradingView

biopharma deals and challenges emerge in asia with focus on adc developments

Roche has entered a $1 billion deal with Innovent Biologics for the DLL3-targeted ADC IBI3009, following promising data from Zai Lab's DLL3 ADC in small cell lung cancer. AstraZeneca faces scrutiny in China, potentially impacting operations, while Viatris received an FDA warning letter for its Indian plant, affecting 11 products. In other developments, Ideaya Biosciences is paying $75 million for rights to SHR-4849, and Hutchmed is divesting its interest in a traditional medicine unit to focus on ADCs.
Fierce Pharma
VBI Vaccines Inc. Shanghai Pharmaceuticals Holding Co., Ltd Hoffmann-La Roche AG Lonza Group AG AstraZeneca PLC I-Mab SK bioscience Co.,Ltd. Zai Lab Ltd IDEAYA Biosciences, Inc. Brii Biosciences Ltd. HUTCHMED Sanofi BeiGene, Ltd. Innovent Biologics, Inc. Viatris Inc. Cytokinetics, Incorporated CHN IND Yong Ying-I Pascal Soriot Show more
Healthcare, News Article
14:37 03.01.2025

Global Generic Pharmaceuticals Market Sees Growth in Simple Generics and Biosimilars

India's "Pharmaceuticals Mission" aims to boost generic production, with simple generics leading the market due to cost-effectiveness and ease of manufacturing. Cardiovascular diseases drive demand, while small molecules dominate product types. Retail pharmacies remain the preferred distribution channel, and key players like Cipla and Teva are expanding their offerings.
GlobeNewswire News Room
United States Dollar Euro Fresenius Kabi AG Sanofi Aspen Pharmacare Holdings Ltd Sun Pharmaceuticals, Ltd. Aurobindo Pharma Limited Glenmark Pharmaceuticals Limited Pfizer Inc. Lupin Limited Dr. Reddy's Laboratories Limited Zydus Lifesciences Limited Teva Pharmaceuticals, Inc. Viatris Inc. Novartis AG Hikma Cipla Limited IND USA Show more
Healthcare, Market Report
16:30 04.12.2024

Greenlight Capital Reports Loss Amid Strong Market Gains in November

Greenlight Capital experienced a 1.8% loss in November, bringing its year-to-date gain to 9%, as the fund maintained a conservative stance amid rising market valuations. Despite strong performances from major long positions, including Kyndryl Holdings and Liberty Global, the fund's short and macro strategies likely faced significant losses, particularly due to a decline in gold prices.
Institutional Investor
United States Dollar Euro Swiss Franc Kyndryl Holdings, Inc. CNH Industrial N.V. CONSOL Energy Inc. Solvay SA Viatris Inc. Liberty Global Ltd. Brighthouse Financial, Inc. USA CHE BEL David Einhorn Show more
Finance & Economy, Market Report
17:34 02.12.2024

david einhorn discusses cautious market strategies at delivering alpha summit

David Einhorn, the hedge fund investor and founder of Greenlight Capital, reported a 9% return in 2024, significantly trailing the S&P 500's over 20% gain. He remains cautiously positioned in what he describes as the most expensive stock market since Greenlight's inception, focusing on opportunities in stocks like Alight and Viatris while maintaining a large gold position amid inflation concerns. Einhorn will share his insights on equity valuations and inflation at CNBC’s Delivering Alpha Investor Summit in New York City.
CNBC
Viatris Inc. Peloton Interactive, Inc. David Einhorn Paul Tudor Jones
Finance & Economy, Market Report
21:14 12.11.2024

teva reports strong generics demand raises 2024 revenue outlook

Teva Pharmaceuticals reported a 13% revenue increase in Q3, reaching $4.3 billion, driven by strong demand for its generics, particularly in the U.S. The company raised its full-year revenue guidance to $16.1-$16.5 billion, bolstered by successful products like Austedo and upcoming biosimilars, including Selarsdi and Simlandi. CEO Richard Francis emphasized a renewed focus on growth strategies to sustain this momentum.
BioSpace
United States Dollar Teva Pharmaceuticals Viatris Inc. AbbVie Inc. Bristol-Myers Squibb Company Novo Nordisk A/S Johnson & Johnson USA ISR Richard Francis AbbVie Johnson & Johnson Show more
Healthcare, Market Report
14:46 07.11.2024

lexicon sells rights to cardio drug to viatris amid restructuring efforts

Lexicon Pharmaceuticals has sold the rights to its cardio drug, sotagliflozin, to Viatris for $25 million upfront, with potential milestone payments of up to $200 million. This move comes as Lexicon restructures and aims to expand into Type 1 diabetes, with an FDA advisory panel set to review the drug's use in this area on October 31. The approval could unlock a $400 million U.S. market for the drug, which is currently marketed as Inpefa for heart failure and related conditions.
BioPharma Dive
United States Dollar Eli Lilly and Company Viatris Inc. Food and Drug Administration Jefferies Financial Group Inc. Lexicon Pharmaceuticals, Inc. USA Jeff Wade Andrew Tsai Show more
Healthcare, News Article
13:15 17.10.2024
Trending
Subcategory
Stock Market Updates Corporate News Industry Trends Finance Mergers & Acquisitions Hedge Funds & Private Equity Global Trade Developments Global Financial Events Market Analysis and Predictions Financial Scams and Security Government Policies Banking Regulations CEO Changes Economic Sanctions Retail and Consumer Goods Startups & Entrepreneurship Industry Mergers & Acquisitions Workplace Trends International Relations Central Bank Actions Government Economic Policies
Countries:
USA CHN IND GBR JPN CAN ARE DEU TWN ITA PRT EGY BEL SGP KOR CHE JOR IRN RUS SAU
Companies:
JPMorgan Chase & Co. Tesla, Inc. The Goldman Sachs Group, Inc. Wells Fargo & Company Bank of America Corporation Barclays PLC Apple Inc. Citigroup Inc. Morgan Stanley Berkshire Hathaway Inc. Microsoft Corporation SpaceXCoin USD The Charles Schwab Corporation AMERICAN EXPRESS Amazon.com, Inc. U.S. Bancorp UBS Group AG Banco Santander, S.A. Deutsche Bank Money Market PP Citizens, Inc.
Currencies:
United States Dollar Euro Indian Rupee Chinese Yuan Japanese Yen British Pound Sterling South Korean Won Swiss Franc United Arab Emirates Dirham Canadian Dollar Israeli New Shekel Swedish Krona Mexican Peso New Taiwan Dollar Egyptian Pound
People:
Donald Trump Elon Musk Warren Buffett Jerome Powell Matteo Salvini Sara Wechter Troy L Rohrbaugh Stacey Friedman Robin Leopold Peter Navarro James L Chosy Michael Feroli Mark Mason Jeff Bezos Mark Zuckerberg Tom Scholar Joe Biden Anand Selvakesari Andrew Cecere Terrance R. Dolan

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.